Comparison of efficacy of Infliximab and Etanercept on Rheumatoid Arthritis patients
- سال انتشار: 1400
- محل انتشار: فصلنامه تحقیقات روماتولوژی، دوره: 6، شماره: 1
- کد COI اختصاصی: JR_RHRE-6-1_004
- زبان مقاله: انگلیسی
- تعداد مشاهده: 283
نویسندگان
Department of Rheumatology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Department of Rheumatology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
چکیده
This study aimed to compare the efficacy of infliximab and etanercept in rheumatoid arthritis (RA) patients to help clinicians select the most effective treatment options. This was a cross sectional study conducted in Urmia, Iran, from March ۲۱, ۲۰۱۷, to February ۲۰, ۲۰۱۸. Data was collected by checklists from RA patients referred to the Rheumatology Clinic of Urmia Imam Khomeini Hospital who were receiving either infliximab or etanercept. Inclusion criteria were a diagnosis of RA according to the revised ۲۰۱۶ criteria of the American College of Rheumatology (ACR)/European League Against Rheumatism, aged over ۱۸, consent to participate in the study, and poor response to other drugs. Both genders were included. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender joint count (TJC), swollen joint count (SJC), and disease activity score (DAS) (۲۸ scores) were analyzed before and after treatment. In a total of ۴۴ eligible patients, ۱۳ patients received infliximab and ۳۱ received etanercept. The mean age was ۵۳.۹۲ ± ۱۰.۹۴ and ۵۲.۸ ± ۶۴.۱۳ years in the infliximab and etanercept groups, respectively. No significant differences were reported concerning ESR (p value = ۰.۹۷) or CRP (p value = ۰.۹۶), while a significant decrease in the infliximab group compared to the etanercept group was demonstrated in terms of DAS۲۸ scores (p value = ۰.۰۲۸), global health (GH)۱ (p value = ۰.۰۰۵), SJC (p value = ۰.۰۰۸), and TJC (p value = ۰.۰۱). This study demonstrated a significant difference between the two groups in the DAS scores ۲۸, SJC, TJC, and GH.کلیدواژه ها
C-reactive protein, Erythrocyte Sedimentation Rates, Rheumatoid arthritisاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.